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Introduction
Bone marrow (BM) contains two different types of stem cell 
populations, hematopoietic stem cells (HSC) and non-hematopoietic 
cells; among the latter, mesenchymal stem cells (MSC) provide 
an appropriate microenvironment to HSC. MSC are multipotent 
progenitors capable of differentiating into a number of cell lineages, 
including bone, cartilage, tendon, muscle or adipose tissue [1-3]. Given 
their multipotentiality, MSC may be considered a powerful resource 
for tissue repair and gene therapy.
In recent years, further interest in MSC has been raised by the 
observation that they exhibit profound immunosuppressive abilities in 
vitro and in vivo. MSC are weakly immunogenic in humans, even when 
infused after allogeneic HCT [4,5]. In vitro, MSC support hematopoiesis 
and inhibit T-cell proliferation [6], NK cell cytotoxicity [7], and 
dendritic cell differentiation [8,9]. In animal models, co-infusion of 
MSC have been shown to facilitate engraftment of human cord blood 
CD34+ cells in non-obese diabetic/severe combined immunodeficient 
(NOD/SCID) mice [10], to prolong skin allograft survival in baboons 
[11], and to prevent aGVHD in some mice models [12] as well as in 
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properties in different settings including hematopoietic cells or solid organ transplantation, and severe or refractory 
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a xenogeneic (human into NOD/SCID mice) model of GVHD [13], 
perhaps by promoting the generation of regulatory T cells [12,14].
In addition, phase II studies in humans have demonstrated that 
MSC infusions were safe [15-17], and might accelerate lymphocyte 
recovery and prevent graft failure after haploidentical HCT [18]. 
Further, MSC infusions have also shown promising efficacy in patients 
with steroid-refractory aGVHD [19], although a recent industry-
sponsored trial failed to show improvement of survival by MSC in that 
setting [20]. 
Although MSC are present in low numbers in the BM (0.01% 
to 0.001% depending on age), they can be easily isolated and when 
exploiting their adhesive property are capable of proliferation and 
expansion in vitro.
In the Laboratory of Cell and Gene Therapy (LTCG, CHU of 
Liège), we started in late 2006 a “MSC bank” based on clinical-grade 
expansion of MSC from BM samples obtained from healthy volunteer 
donors. Cells are produced according to the European Group for Blood 
and Marrow Transplantation (EBMT) consortium recommendations 
for defining common procedures for MSC isolation and expansion, 
as well as common release criteria, enabling multicenter trials with 
comparable MSC products [19]. Indeed, because MSC are believed 
to act mainly by secreting soluble factors, MSC preparation (MSC 
origin, culture media, type of serum supplementation, and extent of ex 
vivo expansion) may have a very significant impact on their ability to 
produce specific soluble factors.
Our first clinical protocol tested the safety and preliminary 
efficacy of MSC to prevent graft rejection and GVHD after allogeneic 
hematopoietic cell transplantation (HCT) with nonmyeloablative 
conditioning [21]. We are currently involved in 6 clinical trials of 
MSC infusion in different settings including HSC transplantation 
(HCT) with myeloablative or non-myeloablative conditioning, cord 
blood transplantation (CBT), solid organ transplantation and severe or 
refractory autoimmune disorders such as Crohn’s disease. According 
to each protocol, the MSC dose varies from 1 to 4x106 MSC/kg patients 
per infusion.
The large numbers of ex-vivo expanded cells that are required in 
these clinical cell therapy protocols make standard culture conditions 
difficult, resulting in the need for extensive personnel and facility 
resources, and the potential for contamination. Indeed, large scale 
cultures in T-flasks are difficult to manage and very time-consuming.
For these reasons, we decided to evaluate the Quantum® device 
from Terumo BCT. This is a robust, functionally closed, automated 
hollow fiber bioreactor system designed to reproducibly grow both 
adherent and suspension cells in either GMP or research laboratory 
environments. 
The aim of the present study was to compare our “traditional” 
T-Flask clinical-grade MSC expansion process with expansion 
in the Quantum® device. All the release criteria for clinical-
grade MSC production were evaluated including: microbiological 
contamination (sterility, mycoplasma and endotoxin), morphology, 
viability, phenotype, karyotype, immunosuppressive properties 
and differentiation potential. Additionally, proliferation rates and 
production rates at harvest were also compared.
Materials and Methods
Donors
The study was approved by the human and animal Ethics 
Committees of the University of Liege. Written informed consent 
was obtained from all bone marrow donors in accordance with the 
Declaration of Helsinki. Donor eligibility was fully evaluated as per 
standard procedures.
MSC traditional clinical-grade culture process
Bone marrow (BM) cells were obtained by BM aspirates drawn 
from the iliac crest of adult volunteers. MSC expansion cultures were 
performed as described by other groups of investigators [19]. Briefly, BM 
(30-50 mL) was collected under local anesthesia in sterile conditions, 
and put in sterile heparin-containing syringes. Mononuclear BM cells 
were isolated by Ficoll centrifugation (GE Healthcare-Amersham 
Biosciences AB, Upsala, Sweden), seeded in sterile tissue culture flasks 
(BD Falcon, Bedford, MA), and cultured in Dulbecco’s Modified 
Eagles Medium-Low Glucose (DMEM, Invitrogen, Merelbeke, 
Belgium) with glutamax supplemented with 10% irradiated fetal 
bovine serum (Hyclone-Perbio Science, Merelbeke, Belgium) and 
antibiotics (penicillin/streptomycin, Lonza Bio Science, Verviers, 
Belgium). Cultures were maintained at 37°C in humidified atmosphere 
containing 5% CO2 for a total of about 4 weeks. The medium was 
replaced twice a week and, after approximately 2 weeks, the cultures 
were near confluence (>70%). Cells were then detached by treatment 
with 0.05% trypsin-EDTA (Invitrogen, Merelbeke, Belgium) and 
replated (first passage) at a lower density to allow further expansion. A 
second passage was performed one week later; when the cells reached 
again confluence (>70%). After 2 fruitful passages (generally 4 weeks 
of culture), the cells were harvested, washed, and resuspended using 
phosphate-buffered saline (PBS)-EDTA (Miltenyi Biotec, Utrecht, The 
Netherlands) and Human Serum Albumin (HSA; CDF-CAF, Brussels, 
Belgium). MSC were then frozen in a medium containing 70% PBS, 
20% HSA, and 10% DMSO (WAK-Chemie, Steinbach, Germany) by 
standard techniques.
The following analyses were performed as quality controls for each 
MSC expansion culture: nucleated cell count on a manual cell counter, 
flow cytometry analysis with determination of the % cells (on total 
cells) positive for CD73, CD90, and CD105, and negative for HLA-DR, 
CD31, CD80, CD14, CD45, CD3, and CD34; cell viability by trypan 
blue exclusion; microbiology testing, including standard virology, 
bacterial culture, and search for mycoplasma; endotoxin detection by 
the limulus test; and cytogenetics. Further, MSC differentiation into 
adipocytes, osteocytes, and chondrocytes [3] as well as inhibitory 
effects of MSC on T-cell proliferation in MLR assays were evaluated 
after some MSC expansions.
MSC Quantum® automated expansion system
The Quantum bioreactor culture system comprises a synthetic 
hollow fiber bioreactor that is part of a sterile closed-loop circuit for 
media and gas exchange. The bioreactor and fluid circuit are a single-
use disposable set that is mounted onto the Quantum® system unit. 
The bioreactor itself is formed by ~11,500 hollow fibers with a total 
intracapillary (IC) surface area of 2.1 m2. Typical culture manipulations 
(e.g., cell seeding, media exchanges, trypsinization, cell harvest, etc.) 
are managed by the computer-controlled system using pumps and 
automated valves, which direct fluid through the disposable set and 
exchanges gas with the media. The functionally closed nature of the 
disposable set is maintained through the sterile docking of bags used 
for all fluids; these bag connections/disconnections all utilize sterile 
connection technology. Gas control in the system is managed using a 
hollow fiber oxygenator. Gas is supplied from a user-provided premixed 
gas tank. By choosing a tank with the desired gas mixture, the user can 
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expand cells at their optimal gas concentration. The IC membrane of 
the bioreactor is coated with an adhesion promoter (fibronectin) to 
allow the attachment of adherent cell populations.
We used the system for the ex vivo expansion of clinical-scale 
human MSC. BM or MSC from pre-expanded cells were expanded in 
the system with the same media than for traditional T-flasks. 
In the Quantum® device process, a single-use disposable set is 
mounted onto the Quantum® system unit for each step of the culture 
(P0, P1 and P2) and needs to be coated overnight with 10 mg of human 
fibronectin (BD Biosciences, Germany) to promote cell adhesion. 
P2 is generally multi-step because, following recommendations of 
the manufacturer; each disposable is ideally loaded with 20x106 pre-
selected MSC. As cells are not visible in the hollow fiber, confluence 
is estimated according to glucose consumption and lactate generation 
by the cells in the system. Fresh complete media is added continuously 
to cells and the inlet rate is adjusted as required by the rate of glucose 
consumption and lactate generation. 
Doubling time estimation
Doubling time (DT) was calculated according to the formula 
DT=txlog (2)/log (number of cells harvested/number of cells 
inoculated)
where, t is the time in hours between initial plating and harvest for 
the respective passage.
Phenotypic characterization of MSC
Flow cytometry analysis was performed for each MSC product 
harvested after expansion in the Quantum® device or in T-Flasks and the 
% of cells positive for CD73, CD105, CD90 and negative for HLA-DR, 
CD14, CD45, CD3 and CD34 was determined on total cells. Phenotype 
analysis was performed in the laboratory of immunohematology of the 
hospital (Prof. Gothot).
Mesenchymal stem cell differentiation assays
Fat, bone and cartilage differentiation assays were carried out as 
described by Pittenger et al. [3] and revealed by staining with oil red O, 
alizarin red and toluidine blue, respectively.
MSC immunosuppression assays
Ten thousand MSC were plated in triplicates in round-bottom 96-
well plates (Becton Dickinson) in a total volume of 100 μl of RPMI 1640 
medium supplemented with 10% FBS,100 U/ml penicillin, 100 mg/ml 
streptomycin, L-glutamine (2 mM) all from Lonza, sodium pyruvate 
(100 mM), non-essential amino acid (NEAA) (100 mM) and 5×10-5 M 
β-mercaptoethanol (β-ME) all from Gibco, Merelbeek, Belgium. After 
4 hour incubation, MSC were irradiated at 25 Gy using a 137 Cs source 
(a GammaCell 40, Nordion, Ontario, Canada).
Allogeneic human peripheral mononuclear cells (PBMC) were 
isolated from blood by Ficoll Paque Plus® density gradient. PBMC 
(5x104 or 1x105) were then added to wells in a total volume of 200 
μl containing or not irradiated MSC, in the presence of anti-αCD3/
CD28 microbeads (Invitrogen, Dynal A/S, Oslo, Norway). Co-cultures 
without anti-αCD3/CD28 microbeads were used as controls. Cells 
were then incubated at 37°C in 5% humidified air for 4 days. Cell cycle 
analysis of PBMC stimulated or not with anti-αCD3/CD28 microbeads 
and cultivated during 4 days with or without MSC were performed 
using CycleTEST Plus® DNA Reagent Kit (Becton Dickinson). 
The percentage of cells in the different phases of the cell cycle was 
determined with the Macsquant Software (Miltenyi) or the Modfit 
Software (Becton Dickinson). The effect of MSC on PBMC stimulation 
responses was calculated as percentage suppression compared with the 
proliferative response in the positive control without MSC (± standard 
deviation of the mean). The positive control was set to 0% suppression.
Cytogenetics
Karyotyping was realized at the Department of Cytogenetics of the 
University Hospital of Liège by the Q-banding technique and analyzed 
with Cytovision® software.
Microbiology testing
MSC sterility was assessed by bacterial culture (aerobic, anaerobic 
and fungal culture with Bactalert®, Organon Teknika Benelux), 
detection of mycoplasma (luminometry, Mycoalert®, Lonza Bio 
Science, Verviers, Belgium) and endotoxin detection (Limulus test).
Lactate and glucose analysis
Lactate concentration in cell culture supernatant was measured using 
the Lactate Pro Blood Lactate Test Meter (Arkray Inc., Amstelveen, The 
Netherlands) following the manufacturer’s instructions. The Lactate 
Pro Test Strip (Arkray) has a measuring range of 0.8–23.3 mmol/L 
and conforms to Directive 98/79/EC. Glucose concentration in cell 
culture supernatants was analyzed using the Contour Blood Glucose 
Monitoring System (Bayer Vital GmbH, Leverkusen, Germany) which 
has a measuring range of 10-600 mg/dL and was used according to the 
manufacturer’s instructions.
Statistical analyses
Cell population doubling times in the various MSC culture 
conditions (Flask fresh cells, Flask thawed cells, Quantum thawed cells 
20 (loaded at 20x106 cells/device), Quantum thawed cells 50 (loaded 
at 50x106 cells/device)) were compared using Mann-Whitney tests. 
Statistical analyses were performed with the GraphPad® Prism 5.00 
Software (La Jolla, CA).
Results 
MSC culture in Quantum® or flasks: fresh bone marrow 
A fresh BM sample was divided in two parts: 25 ml were loaded on 
the Quantum® device while 25 ml were submitted to Ficoll isolation 
of mononuclear cells (MNC). MNC were divided in two parts: first 
part of the cells was seeded in flasks according to our traditional 
culture process and the second part of the cells was loaded on a second 
Quantum® device (Figure 1). After 14 days, cells were harvested. As 
shown in Figure 1, we were able to obtain cells in the Quantum® device 
only with crude bone marrow but not with post-Ficoll MNC. A total 
of 12.6x106 cells were harvested from the Quantum® device (P1Q cells, 
corresponding to 25 ml BM) and 9.8x106 cells were obtained in flasks 
from MNC (P1F cells, corresponding to 12.6 ml BM) (Table 1).
As we only had two devices available to proceed to all our 
experiments (these were lent by Terumo BCT for evaluation), we had 
to freeze and thaw cells between two culture steps (or one machine only 
could be used each time). Indeed, the disposable needs to be coated 
overnight before loading of the cells (fresh cells, blue boxes, and thawed 
cells, green boxes, Figure 1).
P1 Quantum cells (P1Q cells) were thus frozen and then thawed 
before being seeded in a new disposable while P1 flasks cells (P1F cells) 
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were freshly replated at a lower density in flasks (Figure 1). After 7 days, 
cells were harvested from both culture systems. Cells grew faster in the 
Quantum® device with a doubling time (DT) of 40 hours (154x106 
harvested cells from 8.2x106 seeded cells, P2Q cells) compared to 56 
hours in flasks (76x106 cells harvested from 9.7x106 seeded cells, P2F 
cells) (Table 1).
P2Q cells were then frozen in aliquots while P2F cells were freshly 
replated. Three separate experiments were initiated in Quantum each 
with 20x106 thawed P2Q cells as recommended by Terumo BCT (Figure 
1). Cells were allowed to grow 7 days before harvest. Between 110 and 
172x106 cells were obtained in these 3 runs (DT ranging from 54 to 68 
hours). Doubling time in flasks was 64 hours (Table 1). When thawed 
cells from the same aliquots (P2Q) are seeded in parallel in flasks and in 
the Quantum® device, cells grow 2 to 4 times faster in Quantum® than 
in flask (data not shown).
Cell viabilities throughout the whole process were excellent ranging 
from 89 to 100% (Table 1).
MSC were also tested for quality controls at harvest after P1 
and P2 expansions. Sterility, mycoplasma, endotoxin detection, 
Bone Marrow 
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Figure 1: Comparison between culture processes in the Quantum® device and traditional flasks: MSC culture from fresh bone marrow (P0, P1 and P2 expansion 
steps): study design From 50 ml of initial fresh BM, 25 ml were loaded on the Quantum® device while 25 ml were submitted to Ficoll isolation. MNC were divided 
in two parts: the first part was seeded in flasks and the second part on a Quantum® device. After a P0 expansion of 14 days, cells were harvested and re-loaded 
freshly (flasks) or after a freezing/thawing step (Quantum) for P1 expansion. After harvesting 7 days later, cells were re-loaded according to the same scheme for P2 
expansion step(s) in flasks or the Quantum® device. On day 28, cells were harvested and analyzed.
Expansion step Days of culture Cell seeded Cell harvested Viability Doubling time (h) Number of doublings
P0 Flask Fresh cells 14 252 E+06 (12.6 ml Ficoll BM) 9.8 E+06 (P1F) 100% NA NA
Quantum Fresh cells 14 25 ml (whole BM) 12.3 E+06 (P1Q) 92% NA NA
P1
Flask Fresh cells 7 9.7 E+06 (P1F) 76 E+06 (P2F) 98% 56 3.0
Quantum Thawed cells 7 8.2 E+06 (P1Q) 154 E+06 (P2Q) 97% 40 4.2
P2 Flask Fresh cells 7 70 E+06 (P2F) 425 E+06 (P3F) 90% 64 2.6
P2
Quantum Thawed cells 7 20 E+06 (P2Q) 169 E+06 (P3Q-1) 93% 54 3.1
Quantum Thawed cells 7 20 E+06 (P2Q) 172 E+06 (P3Q-2) 89% 54 3.1
Quantum Thawed cells 7 20 E+06 (P2Q) 110 E+06 (P3Q-3) 89% 68 2.5
Table 1: Results for P0, P1 and P2 expansions. This table compares MSC expansion results between the Quantum® device and traditional flasks for all expansion steps 
(Figure 1).
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and karyotyping were performed. All the MSC populations (P3Q 
and P3F) satisfied to release criteria as they were sterile devoided of 
mycoplasma and endotoxin and no abnormal cell clone was detected. 
It wasn’t possible to obtain a karyotype for all cell populations due to 
low numbers of mitoses in some cases. MSC phenotypes (Table 2) also 
satisfied to the ISCT release criteria (> 95% of CD90, CD105, CD73 
expression and <2% CD14, CD34, CD45 and <1% CD3 expression) 
[22].
In conclusion for this first set of experiments, the Quantum® device 
seems to allow higher proliferation rates than flasks except for primary 
cultures (P0 expansions) and MSC produced with the device satisfy to 
the usual release criteria of MSC.
P2 Quantum® or flask expansion: P2 flask thawed MSC 
(20x106 cells)
To test the reproducibility of the device and compare post-thawed 
MSC expansion between both methods, 3 separate identical bags 
containing frozen P2 flask MSC were thawed and 20x106 cells (P2FT 
cells) were loaded on the Quantum® device while the remaining cells 
were seeded in flasks (Figure 2). Cells were allowed to grow for 7 to 9 
Antigen Specification
P1 expansion P2 expansion (3)
P2Q P2F P3Q-1 P3Q-2 P3Q-3 P3F
CD105 >95 98 98.5 98.6 98.4 98.4 99.5
CD90 >95 96.3 99.6 99.7 99.7 98.5 99.8
CD73 >95 99.6 99.5 99.6 99.7 99.6 99.8
CD34 <2 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000
CD45 <2 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000
CD3 <1 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000
CD14 <2 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000
HLA-DR / <1 <1 <1 <1 <1 <1
Table 2: Expression (%) of cell-surface antigens of Q-MSC and F-MSC. Results are shown for P2 and P3 MSC expanded in flasks or the Quantum® device (Figure 1).
 
Quantum 
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P2 expansion 7 days
Fresh cells
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Figure 2: Comparison between culture processes in the Quantum® device and traditional flasks: MSC culture from thawed P2 MSC expanded from fresh cells (20x10-6 
cells/Quantum). After P0 and P1 expansion in flasks from fresh BM, cells were frozen. Three bags containing frozen P2 MSC from flasks from the same donor were 
thawed and cells were seeded in parallel in flasks (80x10E-6 MSC) or Quantum® devices (20x10-6 MSC). Results were also compared with those previously obtained 
after P2 from fresh cells from the same donor.
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days (Table 3) before harvest and quality control assessment.
P3Q cells were harvested after 7 days while 8 or 9 days were 
necessary before harvesting P3FT cells. Results were also compared 
with those previously obtained with fresh cells from the same donor (7 
day expansion; P3F cells) (Figure 2 and Table 3). As already observed, 
doubling times were shorter in Quantum® (44 to 54 hours) than in 
flasks (132 to 190 hours with thawed cells and 64 hours with fresh cells 
(Table 3)
P3Q cells and P3F cells satisfied to release criteria but all karyotypes 
were not interpretable because the number of mitoses didn’t reach 
significance. Phenotypic analysis of the cells also satisfied to the release 
criteria (Table 4).
Each run with the Quantum® device allowed us to harvest from 
170x106 to 276x106 cells. 
P2 Quantum® or flask expansion: P2 flask thawed MSC 
(50x106 cells)
In order to obtain higher numbers of cells in the Quantum®, we 
increased the number of loaded cells. Three P2 frozen MSC bags were 
thawed. For each of them, 50x106 cells were loaded on the Quantum® 
and, for 2 of the 3 bags, the remaining cells were seeded in flasks. 
Results were also compared with those obtained previously with fresh 
cells from the same donors (Figure 3 and Table 5).
P3Q cells were harvested and after 7 or 8 days while P3F cells 
needed to proliferate 8-10 days before harvest (7 days for fresh cells). 
For each of the Quantum® runs, we obtained between 291x106 and 
334x106 MSC, which corresponds to 2 or 3 MSC infusions for a patient. 
DT ranged from 65 to 75 hours for Quantum® (P3Q-1A, P3Q-1B and 
P3Q2 cells), 170 to 294 hours for flasks with frozen cells (P3FT-1A and 
P3FT-1B cells) and between 73 and 98 hours for fresh cells (P3F1 and 
P3F2 cells, Table 5). Proliferation was thus higher in Quantum® than in 
flasks even if we consider fresh cells. Viabilities were very good, ranging 
from 82 to 95%.
In conclusion, it was possible to increase the number of harvested 
cells when we loaded onto the Quantum® more than the initially 
recommended number of cells (50x106 instead of 20x106) without 
impairing compliance to all release criteria (Tables 4 and 6), without 
clotting and keeping interesting harvest rates.
When we tried to further increase the number of loaded cells to 
80x106 cells, harvested cells were of poor quality, with aggregates and 
debris (data not shown). 
Comparison between MSC doubling time in different 
conditions
We compared cell population doubling times in the various 
culture conditions. Doubling times in flasks were 75 ± 16 hours with 
fresh cells vs. 185 ± 65 hours with thawed cells (p=0.0159). Doubling 
Expansion step Days grown Cell seeded Cell harvested Viability Doubling time (h) Number of doublings
P2 Fresh cells Flask 7 140 E+06 (P2F) 870 E+06 (P3F) 95% 63 2.6
P2 Thawed cells
Quantum 7 20 E+06 (P2FT) 276 E+06 (P3Q-1) 93% 44 3.8
Flask 8 80 E+06 (P2FT) 209 E+06 (P3FT-1) 95% 138 1.4
Quantum 7 20 E+06 (P2FT) 178 E+06 (P3Q-2) 97% 53. 3.2
Flask 9 80 E+06 (P2FT) 249 E+06 (P3FT-2) 95% 132 1.6
Quantum 7 20 E+06 (P2FT) 170 E+06 (P3Q-3) 78% 54 3.1
Flask 8 80 E+06 (P2FT) 161 E+06 (P3FT-3) 95% 190 1.0
Table 3: Results of P2 expansion from P2 thawed MSC in the Quantum® device or traditional flasks. Results were also compared with those obtained after P2 from fresh 
cells from the same donor (Figure 2).
Antigen Specification
Fresh cells Thawed cells
P3F P3FT-1 P3Q-1 P3FT-2 P3Q-2 P3FT-3 P3Q-3
CD105 >95 99.8 99.4 99.1 99.6 99. 99.6 99.2
CD90 >95 99.9 99.8 99.8 99.8 99.8 99.8 99.8
CD73 >95 99.4 99.3 99.6 99.2 99.7 99 99.6
CD34 <2 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000
CD45 <2 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000
CD3 <1 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000
CD14 <2 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000
HLA-DR / <1 <1 <1 <1 <1 <1 <1
Table 4: Expression (%) of cell-surface antigens of Q-MSC and F-MSC. Results are shown for MSC processed freshly in traditional flasks (F) and for MSC processed after 
a freezing/thawing step at P2 and replated in the Quantum® device (P3Q) or in flasks (P3F) (Figure 2).
Expansion step Days of culture Cell seeded Cell harvested Viability Doubling time (h) Number of doublings
Donor 1 Fresh cells Flask 7 224 E+06 (P2F-1) 1092 E+06 (P3F-1) 84% 73 2.3
Donor 1 Thawed cells
Quantum 7 50 E+06 (P2FT-1) 297 E+06 (P3Q-1A) 92% 65 2.6
Flask 8 50 E+06 (P2FT-1) 109 E+06 (P3FT-1A) 91% 170 1.1
Quantum 8 50 E+06 (P2FT-1) 291 E+06 (P3Q-1B) 95% 75 2.5
Flask 10 42 E+06 (P2FT-1) 74 E+06 (P3FT-1B) 95% 294 0.8
Donor 2 Fresh cells Flask 7 172 E+06 (P2F-2) 560 E+06 (P3F-2) 82% 98 1.7
Donor 2 Thawed cells Quantum 8 50 E+06 (P2FT-2) 334 E+06 (P3Q-2) 94% 70 2.8
Table 5: Results for P2 expansions from P2 thawed MSC in the Quantum® device and traditional flasks. Results were also compared with those previously obtained after 
P2 from fresh cells from the two same donors (Figure 3).
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Antigen Specification
Donor 1 Donor 2
Fresh Thawed Fresh Thawed
P3F-1 P3FT-1A P3Q-1A P3FT-1B P3Q-1B P3F-2 P3Q-2
CD105 >95 99.7 99.5 97.2 99.5 98 99.4 99.1
CD90 >95 99.4 99.9 99.8 99.8 99.9 99.8 99.6
CD73 >95 99.8 99.7 99.8 99.5 99.9 99.5 99.0
CD34 <2 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000
CD45 <2 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000
CD3 <1 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000
CD14 <2 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000 <1/10000
HLA-DR / <1 <1 <1 <1 <1 <1 <1
Table 6: Expression (%) of cell-surface antigens of Q-MSC and F-MSC. Results are shown for MSC processed freshly in traditional flasks (F) and for MSC processed after 
a freezing/thawing step at P2 and replated in the Quantum® device (P3Q) or in flasks (P3F) (Figure 3).
300x106 harvested cells Quantum (thawed cells) Flask (fresh cells) Flask (thawed cells)
Loaded cells 50x106 62x106 138x106
Days in culture 7 7 8
Disposables (kits, bags, flasks) 1 disposable kit+bags 88 flasks 198 flasks
Medium consumption 7,840 mL 5,040 mL 11,200 mL
Working time / run (hours) 8 12 21
Working time/harvest+freezing (hours) 3 7 15
Table 7: Quantum® device and T-flask MSC manufacturing requirements (P2 expansion step). Comparison between Quantum® and T-flask (fresh or thawed cells) 
manufacturing needs considering a P2 expansion step leading to a 300x106 MSC harvest.
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Figure 3: Comparison between culture processes in the Quantum® device and traditional flasks: MSC culture from thawed P2 MSC expanded from fresh cells (50X10-
6 cells/Quantum). After P0 and P1 expansion in flasks from fresh BM, cells were frozen. Three bags containing frozen P2 MSC from P2 flasks from two different 
donors were thawed and cells were seeded in parallel in flasks (80x10-6) or Quantum® devices (50x10-6). Results were also compared with those previously obtained 
after P2 from fresh cells from the same donors.
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times in Quantum devices were 55 ± 8 hours with 20x106 thawed cells 
vs. 70 ± 5 hours with 50x106 thawed cells (p=0.0489). Thawed cells 
cultured in Quantum devices grew faster than thawed cells (p=0.0043 
and p=0.0357, respectively when 20 or 50x106 cells were loaded) or 
even fresh cells (p=0.0381 with 20x106 cells, but NS with 50x106 cells) 
cultured in flasks.
Differentiation
Three samples of P3Q cells and P3F cells were subjected to 
differentiation into osteoblastic, adipocytic and chondrocytic lineages. 
P3Q cells and P3F cells differentiated equally well towards the 3 lineages 
(data not shown).
Immunosuppressive properties
Immunosuppressive properties of MSC were also assessed in 
three samples of P3Q cells and P3F cells. As shown in a representative 
experiment in Figure 4, P3Q and P3F cells displayed similar 
immunosuppressive properties. 
Indeed, proliferation of stimulated PBMC was similarly reduced 
by P3Q or P3F cells (Figure 4A and B), and these results are similar to 
those obtained with fresh cells from the same donor indicating than the 
freezing/thawing step didn’t impair MSC intrinsic immune properties 
(Figure 4C and D). 
Discussion 
In recent years, interest in MSCs has been raised by the observation 
that they exhibit profound immunosuppressive abilities in vitro and 
in vivo. These are thus now evaluated in numerous clinical studies 



































































































































































































 Figure 4: Inhibition of PBMC proliferation by third party MSC: comparison between Q-MSC and F-MSC. PBMC (100,000 or 50,000) were stimulated (S-PBMC) with 
anti-αCD3/CD28 microbeads during 4 days with or without irradiated (25 Gy) MSC (10/1 or 5/1 PBMC/MSC ratios) added at the beginning of the culture. Proliferation 
was assessed by analysis of the cell cycle by flow cytometry. One representative experiment is shown. Result are expressed as the percentage of cells present in 
S+G2M phases (A) and as the percentage of inhibition compared to the stimulated PBMC condition alone (B). Similar results with fresh cells (from flasks) from the 
same donor are shown in (C) and (D).
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The procedure used to prepare MSC for clinical applications are 
based on enrichment of MSC present in bone marrow mononuclear 
cells by plastic adherence, followed by ex vivo expansion in selected 
serum-containing media [24]. As traditional culture in T-flasks is 
quite time-consuming and bulky, we decided to evaluate a new culture 
system in the Quantum® bioreactor from Terumo BCT, notably 
developed for ex-vivo expansion of clinical scale human MSC. Until 
now, few studies have been initiated to evaluate the system. Roberts et 
al. demonstrated that human embryonic stem cells (hESC) culture can 
be scaled up through the use of the bioreactor [25] and two recently 
published studies evaluated the Quantum® device to isolate and expand 
BM-MSC in FCS or platelet lysate (PL)-enriched media in two-step 
processes [26,27]. 
In the present study, we evaluated the Quantum® bioreactor 
system according to our clinical process requirements and results were 
compared with those from cells obtained by our traditional culture 
system in flasks.
Our first goal was to investigate whether it was possible to manage 
the whole culture process from a bone marrow collection (P0) to final 
harvest of MSC (P3) with the system. This is indeed feasible and the 
Quantum® device seems to allow higher proliferation rates than flasks 
in our conditions (excepted for primary cultures P0 expansions). We 
harvested between 110 and 172x106 cells after each P2 expansions (3 
separate runs, 20x106 loaded cells each). 
In a second set of 3 separate experiments, we evaluated the 
reproducibility of the method and the feasibility of expanding P2-
thawed preselected cells (initially obtained in flasks). P2 expansion 
represents the last step of MSC culture leading to harvest of clinically 
usable cells. Each run with the Quantum® device allowed us to harvest 
from 170x106 to 276x106 cells, which represents one or two MSC 
infusion(s) for one patient. 
With these experiments, we have demonstrated that despite some 
differences between the two culture systems, it is possible to produce 
“clinical grade” MSC satisfying to all release criteria with the Quantum® 
device. Indeed, both Flask- and Quantum®-MSC satisfied to all the 
ISCT-release criteria. Q-MSC expressed >95% CD73, CD90 and CD105 
receptors and lacked expression of hematopoietic markers (<2%), such 
as CD34, CD45 and HLA-DR and blood cell lineage-specific antigens, 
such as CD14 (<2%) and CD3 (<1%). Immunosuppressive properties 
and differentiation into fat, bone and cartilage were also similar. 
Cytogenetic analyses were normal, in agreement with the recently 
published study of Jones et al. [28]. 
Rojewski et al. showed that the Quantum® system reliably produces 
a therapeutic cell dose that fulfills MSC criteria in a two-step process. 
Our results are in accordance if we compare expansion of 20x106 
pre-selected cells. Similar DT (around 40 hours) and cellular outputs 
(around 150 x106 MSC) were obtained in both studies. However, when 
they compared growth rates between traditional flask culture and the 
bioreactor, results were in favor of flask culture. In our study, cells grew 
faster in the bioreactor than in flasks. This is probably partially due to 
differences in flask seeding density. In our experiments, we work with 
the EBMT-recommended seeding density of 4,000 cells/cm2. This is 
indeed much more than the seeding density in the bioreactor (a density 
of 950 cells/cm2 is obtained when loading 20x106 cells in a disposable of 
2.1 m2). Moreover, Nold et al., who also worked at a higher density in 
flasks (5,000 cells/cm2) than in the Quantum® bioreactor, also reported 
similar or better DT in the Quantum® system than in flasks [27]. 
Loading 15-20x106 cells per disposable is the most common seeding 
strategy for the Quantum system. This means that for a P2 expansion 
step, it is necessary to freeze cells in adequate aliquots before thawing 
each one for a new expansion run unless several machines are available.
In order to limit freezing/thawing steps, we tried in a third set of 3 
separate experiments to increase the number of loaded cells to 50x106 
P2-thawed flask preselected cells. For each run, we harvested between 
291 and 334x106 MSC, which corresponds to 2 or 3 MSC infusions 
for one patient. Again, cells fulfilled MSC release criteria. Thus, it was 
possible to increase cellular output by increasing the number of loaded 
cells. However, further increasing initial cell loading to 80x106 was not 
possible as it resulted in aggregation of cells with poor viability.
We had two Quantum devices available for our experiments 
and the procedure of the time required an overnight coating with 
fibronectin before loading cells. Therefore, all runs in the bioreactor 
were performed with frozen/thawed cells (except the P0 to P1 step). 
This was a considerable disadvantage as thawed cells proliferate more 
slowly than fresh cells. This suggests that if we had additional devices 
to work with fresh cells, we should probably improve cell output in 
the bioreactors. Rojewski et al. also addressed the question of loading 
cryopreserved versus fresh cells in the bioreactor and they observed, 
in agreement with our results, higher doubling time for cryopreserved 
cells than for freshly pre-expanded MSC. Interestingly, they didn’t 
notice any difference when comparing cytokine level profile of thawed 
compared to fresh cells.
As our banking objective is to produce a maximum amount of 
MSC from a single BM sample without intermediate freezing steps, 
we are confronted with two major hurdles before adopting clinical 
production of MSC in the Quantum® bioreactor, i.e. overnight coating 
of the disposables and the limited number of cells that can be loaded 
on the device. To circumvent these limitations, we have actually two 
possibilities. First, we could scale up by working with additional devices 
(for example a minimum of 4 devices would be necessary for a 200x106 
P2 expansion) or we could freeze cell aliquots at each passage and 
thaw them later for further expansion in separate runs. However, these 
supplemental steps are time-consuming and also induce additional 
costs. Indeed, some preparative tasks such as bag filling and installation 
of the disposable for example need to be repeated and a new disposable 
is required for each run. Table 7 compares MSC manufacturing 
requirements between the Quantum® bioreactor and T-flasks (fresh or 
thawed cells) considering one P2 expansion step leading to a 300x106 
MSC harvest. Main disposables (kit, bags, T-flasks), media, reagents 
and working time were considered. In our strategy, costs are still 4 to 
8 times higher using the bioreactor as compared to T-flasks (mainly 
due to the cost of the disposable kit) for expansion of fresh or thawed 
cells, respectively, despite a reduced working time with the Quantum® 
device (essentially at the harvesting step). The purpose of our study 
was to compare the process currently used for our clinical grade 
MSC production with a fully closed bioreactor system. However, an 
interesting option could also be to compare the bioreactor with the 
Cellstacks® (Corning) or Cellfactories® (Nunc) widely used by others. 
These are also open systems but probably allow managing more cells in 
a shorter time period [21]. 
In conclusion, the major advantages of the bioreactor are that (1) 
cells can grow better in the Quantum® than in flasks, (2) working time 
is shorter especially at the final harvest step, and (3) all the feeding 
tasks are done automatically. This system can thus allow production 
of MSC according to good manufacturing practice (GMP), but we 
have encountered limitations in the attempt to directly translate our 
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established manufacturing strategy. For our particular situation, the 
use of the Quantum device didn’t result in a cost-saving solution.
Thus to adopt the system in our facility, increasing the capacity 
of the bioreactor and thus cell output is necessary so that the cost 
balance is reversed. Such new developments have just been evaluated 
at TerumoBCT. First, a new seeding protocol has been developed for 
the device leading to an increased harvesting rate. Second, shorter 
coating of the disposable (4 hours instead of overnight) is now feasible. 
This will probably allow laboratories to work with fewer devices and 
to avoid freezing/thawing steps, thereby increasing proliferation rates 
and cell recovery. 
Our study was designed to compare MSC cultures in T-flasks and in 
a bioreactor system and to optimize cultures in the Quantum Device®, 
for clinical purposes. Hence, cultures were stopped after passage 2 
and quality controls were those usually recommended for clinical 
grade MSC expansion products [19,21,24,29]. However, for research 
purposes, it would be interesting to evaluate cultures at later passages 
as published results suggest that late passage MSC are less effective than 
early passage due to cell senescence [30-32]. MSC characterization 
could then also be more refined as cells expanded in different in 
vitro systems may have different in vivo behaviour even if they have 
comparable phenotypes and differentiation abilities. Quantification of 
intracellular proteins of interest and measurements of secreted factors 
(among which SCF, IL-6, SDF-1, TGF-β1, RANTES, βFGF, …) should 
be interesting for further understanding MSC biology in these various 
expansion systems.
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